Sinopharm Group Co. Ltd. has filed an updated list of directors and their roles with the Hong Kong Stock Exchange. The Board comprises Non-Executive Directors Zhao Bingxiang (Chairman), Chen Qiyu, Zu Jing, Xing Yonggang, Chen Yuqing, Wen Deyong, and Feng Rongli; Executive Director Lian Wanyong (President); and Independent Non-Executive Directors Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru. Committee memberships are as follows: Zhao Bingxiang serves as Chairman of the Nomination Committee and the Strategy and Investment Committee and is a member of the Legal and Compliance and ESG Committee. Chen Qiyu and Wen Deyong are members of the Strategy and Investment Committee, while Chen Yuqing and Lian Wanyong are members of both the Strategy and Investment Committee and the Legal and Compliance and ESG Committee. Feng Rongli is a member of the Remuneration and Nomination Committees. Li Peiyu chairs the Remuneration Committee and is a member of the Audit and Strategy and Investment Committees. Wu Tak Lung chairs the Audit Committee and is a member of the Remuneration and Nomination Committees. Yu Weifeng chairs the Legal and Compliance and ESG Committee and is a member of the Remuneration and Nomination Committees. Shi Shenghao is a member of the Audit, Nomination, and Strategy and Investment Committees. Chen Weiru is a member of the Nomination and Strategy and Investment Committees.